2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

KB 8.5 cell

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0043
    Ginsenoside Rd
    1 Publications Verification

    Gypenoside VIII

    		 NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca 2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd
  • HY-N7675
    Flavanomarein

    		NF-κB TGF-beta/Smad Syk Cardiovascular Disease Neurological Disease Metabolic Disease
    Flavanomarein is a substance with cytoprotective, anti-inflammatory and antioxidant activities, with a Ka of 3.064e-5 M against human Syk. Flavanomarein enhances the phosphorylation level of AKT, regulates the expression of PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2 and ICAD, and inhibits the nuclear translocation of NF-κB p65. Flavanomarein regulates EMT marker proteins, promotes the proliferation of HK-2 cells, and protects neuronal cells from 6-OHDA-induced neurotoxic damage. Flavanomarein can be used in studies related to Parkinson's disease and diabetic nephropathy.
    Flavanomarein
  • HY-W001023
    5-Amino-8-hydroxyquinoline

    5A8HQ; 5AHQ

    		 Proteasome NF-κB Cancer
    5-Amino-8-hydroxyquinoline (5A8HQ; 5AHQ) is an orally active non-competitive 20S proteasome inhibitor. 5-Amino-8-hydroxyquinoline can inhibit NF-κB activity and induce cancer cells death and shows low cytotoxicity towards normal hematopoietic cells. 5-Amino-8-hydroxyquinoline can be used for the research of cancer, such as leukemia .
    5-Amino-8-hydroxyquinoline
  • HY-115062
    MJ33 lithium salt

    		Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    MJ-33 lithium salt is a competitive phospholipase A2 (PLA2) inhibitor with an IC50 of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA2 activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA2 (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA2 (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .
    MJ33 lithium salt
  • HY-107592
    ACHP

    		IKK STAT Apoptosis Inflammation/Immunology Cancer
    ACHP (compound 4j) is a selective and orally active IκB kinase inhibitor with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. ACHP can effectively inhibit the STAT3 signaling pathway and induce cancer cell cycle arrest and apoptosis. ACHP shows anti-inflammatory activity in a mouse ear edema model. ACHP can be used in anti-inflammatory and anti-cancer (such as multiple myeloma and leukemia) studies .
    ACHP
  • HY-177021
    Tubulin-IN-51

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin-IN-51 is an orally available, potent tubulin inhibitor (IC50 = 31 nM). Tubulin-IN-51 promotes tubulin polymerization in vitro and does not compete with Paclitaxel (HY-B0015) for binding. Tubulin-IN-51 inhibits the binding of Vinblastine (HY-13780) to tubulin. Tubulin-IN-51 downregulates the proportion of cells in the G1 phase and induces apoptosis. Tubulin-IN-51 inhibits tumor growth in multiple nude mouse xenograft models .
    Tubulin-IN-51
  • HY-136271
    MJ33

    		Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC50 of 0.3 μM. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer .
    MJ33
  • HY-N16065
    Prenylterphenyllin

    		Bacterial Infection
    Prenylterphenyllin (Compound 1) is an antibacterial agent. Prenylterphenyllin can be isolated from marine-derived fungus Aspergillus candidus IF10. Prenylterphenyllin has cytotoxic activity against KB3-1 cells with an IC50 of 8.5 mg/mL. Prenylterphenyllin also has antibacterial activities against Xanthomonas oryzae and Erwinia amylovora with MICs of both 20 μg/mL .
    Prenylterphenyllin
  • HY-N0043R
    Ginsenoside Rd (Standard)

    Gypenoside VIII (Standard)

    		 Reference Standards NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd (Standard)
  • HY-W001023A
    5-Amino-8-hydroxyquinoline dihydrochloride

    5A8HQ dihydrochloride; 5AHQ dihydrochloride

    		 Proteasome NF-κB Cancer
    5-Amino-8-hydroxyquinoline (5A8HQ; 5AHQ) dihydrochloride is an orally active non-competitive 20S proteasome inhibitor. 5-Amino-8-hydroxyquinoline dihydrochloride can inhibit NF-κB activity and induce cancer cells death and shows low cytotoxicity towards normal hematopoietic cells. 5-Amino-8-hydroxyquinoline dihydrochloride can be used for the research of cancer, such as leukemia .
    5-Amino-8-hydroxyquinoline dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: